This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Interferon beta (IFNβ) treatment in multiple sclerosis (MS) has been associated with hepatotoxicity,1 and there have been reported cases of severe hepatitis induced by IFNβ.2,3 Acute autoimmune hepatitis (AIH) as a side effect of IFNβ therapy in MS is rare.2–4 There are no reported cases of IFNβ unmasking previously undiagnosed chronic AIH. We report a case in which chronic AIH only became symptomatic and diagnosed following the initiation of IFNβ therapy, and early recognition resulted in definitive therapy and an excellent outcome.
Case report.
A 43-year-old woman recently diagnosed with MS was started on IFNβ1a (Rebif) 22 μg TIW, and the dose was increased to 44 μg over 1 month as per routine protocol. She did not have any history of liver disease, alcohol abuse, or illicit drug use, and liver function tests (LFTs) were normal prior to treatment. Despite being told to have liver function tests performed 1 month after initiation of IFNβ, she was not heard from until about 6 weeks after the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS
Acute liver injury in a Glatopa-treated patient with MS
Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis